Drug · DIN 02511096
ABRILADA
SINGLE-DOSE VIAL
Authorized, not yet reported as sold
Authorized for sale in Canada; the company has not yet told Health Canada that it is on the market.
Status Approved since June 29, 2021.
- Drug Identification Number (DIN)
- 02511096
- Company (DIN owner)
- Pfizer Canada UlcKirkland, Quebec, Canada
- Schedule
- Prescription; Schedule D
- Dosage form
- Kit; Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Adalimumab L04AB04
- Class
- Human
- Record last updated
- August 10, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ADALIMUMAB | 40 MG | 0.8 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- January 14, 2021: NOC 25020New Drug Submission (NDS)
Other DINs named ABRILADA
- DIN 02511045 · Marketed
- DIN 02511053 · Marketed
- DIN 02511061 · Marketed
- DIN 02511088 · Approved